(SeaPRwire) – Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
Halle (Saale) / Munich, Germany, September 5, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has completed the reduction of its share capital by decreasing the nominal value of the shares in the Company’s capital to EUR 0.01 from EUR 1.00.
The proposal of the Company’s Board of Directors to amend the Company’s articles of association by, among other items, decreasing the nominal value of the shares in the capital of the Company to EUR 0.01 from EUR 1.00 was approved by the shareholders at the 2024 annual general meeting (AGM), held on June 21, 2024. Following the completion of the creditor opposition procedure in accordance with Dutch law, with no objection having been filed, the Company has now implemented the share capital reduction.
The purpose of the reduction in nominal value is to improve the Company’s capability to attract new financing, pursue M&A activities and incentivize management, members of the Board and employees of the Company through granting equity awards, and also improve the Company’s equity composition, as set out in the Company’s notice of annual general meeting published May 8, 2024.
The nominal value of the shares in the Company is now EUR 0.01 each. The number of ordinary shares of the Company in issue (included shares held in treasury) has not changed and consists of 26,066,809 ordinary shares. The amount of the capital reduction (being: EUR 0.99 per share that formed part of the Company’s issued share capital) has been added to the Company’s distributable reserves. The Company’s updated articles of association have been posted on the Company’s website.
###
關於 Vivoryon Therapeutics N.V.
Vivoryon 是一家臨床階段生物科技公司，專注於開發創新的基於小分子藥物的藥品。在對突破性科學和創新的熱情驅使下，公司努力改變需要幫助的患者的生活，這些患者患有嚴重的疾病。公司利用其在理解轉譯後修飾方面的深入專業知識來開發藥物，調節在疾病環境中發生改變的蛋白質的活性及其穩定性。公司已經建立了口服小分子抑制劑的管道，適用於各種適應症，包括阿爾茨海默病、炎症和纖維化疾病（包括腎臟）以及癌症。.
Vivoryon 前瞻性陳述
本新聞稿包含前瞻性陳述，包括但不限於關於 Vivoryon Therapeutics N.V.（“公司”）的業務策略、管理計劃和未來經營目標、公司產品市場的估計和預測，以及公司產品何時可供使用的預測和陳述。諸如“預期”、“相信”、“估計”、“預計”、“預測”、“打算”、“可能”、“計劃”、“預計”、“預測”、“應該”和“將”等詞語以及與公司相關的類似表達旨在識別此類前瞻性陳述。這些前瞻性陳述不保證未來的業績；相反，它們基於管理層目前對未來事件和趨勢、經濟狀況和其他未來條件的預期和假設。前瞻性陳述涉及許多已知和未知的風險和不確定因素。這些風險和不確定因素以及其他因素可能會對本文所述計劃和事件的結果和財務影響產生重大不利影響。公司的經營成果、現金需求、財務狀況、流動性、前景、未來交易、策略或事件可能與此類前瞻性陳述以及預期中表達或暗示的內容存在重大差異。因此，不應過分依賴此類前瞻性陳述。本新聞稿不包含風險因素。可能會影響公司未來財務業績的某些風險因素在公司已發布的年度財務報表中討論。本新聞稿（包括任何前瞻性陳述）僅在本新聞稿發布之日生效。除法律要求披露的任何信息外，公司不承擔更新本新聞稿中包含的任何信息或前瞻性陳述的義務。
如需了解更多信息，請聯繫：
投資者聯繫方式
Vivoryon Therapeutics N.V.
Dr. Manuela Bader，IR & Communication 總監
電話：+49 (0)345 555 99 30
電子郵件：
媒體聯繫方式
Trophic Communications
Valeria Fisher
電話：+49 175 8041816
電子郵件：
附件
本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。
分類: 頭條新聞,日常新聞
SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。